Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lisa Scaccetti

Nurse Practitioner Levittown, PA Nurse Practitioner

NPI 1366745200 CMS profile 10680256

1 Sugarmaple Ln, Levittown, PA 19055

Open in the dashboard

General payments

$3,664

221 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Scaccetti of Levittown, PA is reported in the CMS Open Payments database as having received $3,664 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $973 44
2024 General $651 37
2021 General $2,040 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Scaccetti
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lisa Scaccetti were reported at $973. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lisa Scaccetti Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,040 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $651 $173 $55–$556 $164
2025 $973 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $599 40 payments
  2. Pfizer Inc. $452 32 payments
  3. AbbVie, Inc. $394 33 payments
  4. Amgen Inc. $300 16 payments
  5. Lilly USA, LLC $239 12 payments
  6. Amarin Pharma Inc. $184 12 payments
  7. Merck Sharp & Dohme Corporation $181 12 payments
  8. Sanofi-Aventis U.S. LLC $160 3 payments
  9. Bausch Health US, LLC $114 6 payments
  10. GlaxoSmithKline, LLC. $101 5 payments
  11. Other $941 50 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,664 221 payments
Products named General payments · program years 2021–2025
  1. COLOGUARD DNA CAPTURE REAGENTS $304 26 payments
  2. ELIQUIS $212 11 payments
  3. RYBELSUS $192 12 payments
  4. UBRELVY $190 21 payments
  5. Vascepa $184 12 payments
  6. Ozempic $173 11 payments
  7. Otezla $162 9 payments
  8. TZIELD $160 3 payments
  9. TRULICITY $132 7 payments
  10. Wegovy $130 9 payments
  11. Other $3,029 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

269

Median for Nurse Practitioner: 389

Drug cost

$3,456

Median for Nurse Practitioner: $21,885

Branded share of claims

20.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Albuterol Sulfate Hfa Albuterol Sulfate Brand 31 $840
Rosuvastatin Calcium Generic 16 $642
Atorvastatin Calcium Generic 30 $374
Lisinopril Generic 29 $276
Moxifloxacin Moxifloxacin Hcl Brand 13 $231
Metoprolol Succinate Generic 14 $230
Amlodipine Besylate Generic 29 $219
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 11 $186
Levothyroxine Sodium Generic 13 $165
Methylprednisolone Generic 21 $89

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$17,467

Of which drugs: $2,309

Medicare patients

115

Average age 71

Services billed

287

83 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 24%
Ischemic heart disease 24%
Depression 20%
Osteoporosis 19%
Cancer 17%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 19 19 $1,555

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $75
$75 — —
Wegovy
  • Novo Nordisk Inc $60
$60 — —
WELLBUTRIN
  • Bausch Health US, LLC $59
$59 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $38
  • Lilly USA, LLC $10
$48 — —
LOREEV XR
  • Almatica Pharma LLC $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record